Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status

Author： Kang Myoung  

Publisher： Springer Publishing Company

ISSN： 0167-6997

Source： Investigational New Drugs, Vol.30, Iss.4, 2012-08, pp. : 1607-1613

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines

By Shitara Kohei  

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 787-793

Springer Publishing Company

Access to resources Recommend Favorite

Phase II study of combination chemotherapy with irinotecan and cetuximab for pretreated metastatic colorectal cancer harboring wild-type KRAS

By Shitara Kohei   Yokota Tomoya   Takahari Daisuke   Shibata Takashi   Ura Takashi   Utsunomiya Setsuo   Inaba Yoshitaka   Yamaura Hidekazu   Sato Yozo   Najima Mina   Kawai Hiroki   Tajika Masahiro   Sawaki Akira   Yatabe Yasushi   Muro Kei  

Investigational New Drugs, Vol. 29, Iss. 4, 2011-08 ,pp. : 688-693

Springer Publishing Company

Access to resources Recommend Favorite

A phase II, multicenter study of cetuximab monotherapy in patients with refractory, metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostaining

By Wierzbicki Rafal   Jonker Derek   Moore Malcolm   Berry Scott   Loehrer Patrick   Youssoufian Hagop   Rowinsky Eric  

Investigational New Drugs, Vol. 29, Iss. 1, 2011-02 ,pp. : 167-174

Springer Publishing Company

Access to resources Recommend Favorite

Weekly irinotecan plus UFT and leucovorin as first-line chemotherapy of patients with advanced colorectal cancer

By Méndez M.   Alfonso P.   Pujol E.   González E.   Castañon C.   Cerezuela P.   López-Mateos Y.   Cruz J.  

Investigational New Drugs, Vol. 23, Iss. 3, 2005-06 ,pp. : 243-251

Springer Publishing Company

Access to resources Recommend Favorite

Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan

By Vincenzi Bruno   Santini Daniele   Russo Antonio   Gavasci Michele   Battistoni Fabrizio   Dicuonzo Giordano   Rocci Laura   Rosaria Valerio Maria   Gebbia Nicola   Tonini Giuseppe  

Pharmacogenomics, Vol. 8, Iss. 4, 2007-04 ,pp. : 319-327

Future Medicine

Access to resources Recommend Favorite